Evidence map›Paper›PMID 42465265›Full record

ArticlebioRxiv : the preprint server for biology2026

A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.

Ximi K Wang, Ajna Uzuni, Lingting Shi, David W Harle, Rodney Macedo, Michael Pressler, Christian A Gordillo, Kirubel Belay, Shami Chakrabarti, Joshua Fuller and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ximi K WangColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Ajna UzuniColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Lingting ShiDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
David W HarleColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Rodney MacedoColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Michael PresslerDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Christian A GordilloColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Kirubel BelayColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Shami ChakrabartiColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Joshua FullerDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Elizabeth O HexnerCenter for Cell Therapy and Transplant, University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA.
Alison W LorenCenter for Cell Therapy and Transplant, University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA.
David L PorterCenter for Cell Therapy and Transplant, University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA.
Markus Y MaparaColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Megan SykesColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Elham AziziDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Ran ReshefColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0003-2185-9546

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Effector T-cell trafficking in graft-versus-host diseaseR01HL143424 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RESHEF, RAN · 2019 to 2023
$2.0M
Organ-specific Ugt1 profiling in detoxifying the anticancer drug CPT-11R21CA171008 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHUJUAN · 2012 to 2013
$361k
NCI NIH HHS P30 CA013696NCI NIH HHS R21 CA171008NHLBI NIH HHS R01 HL143424
6 · The paper itself

Abstract

Acute graft-versus-host disease (GVHD) remains a lethal barrier to successful allogeneic hematopoietic cell transplantation, yet pre-transplant donor selection entirely ignores hypervariable T-cell receptor (TCR) architecture. Here, by characterizing over 64,000 alloreactive clonotypes, we demonstrate that human alloreactivity is dictated by a constrained, predictable baseline structural signature. Pathogenic, tissue-infiltrating alloreactive T cells exhibit significantly shortened CDR3β regions, altered antigen-facing biophysical features, biased VJ gene usage and extensive inter-donor sharing originating from public anti-pathogen memory reservoirs. These potent clones natively cluster within the high-frequency fraction of the unstimulated baseline donor repertoire. We introduce R50, an assay-independent metric quantifying this clonal dominance, which independently predicted a six-fold increased risk of acute GVHD in a cross-institutional cohort. This scalable

Identifiers

PMID42465265
PMCPMC13370999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.